Corestem Inc. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
3,432
6,325
277
1,218
4,755
Depreciation, Depletion & Amortization
357
932
1,072
1,179
1,506
Other Funds
2,100
-
-
-
1,363
Funds from Operations
1,307
89
3,152
854
2,258
Changes in Working Capital
795
2,360
4,171
2,650
4,034
Net Operating Cash Flow
512
2,449
1,020
3,503
6,293
Capital Expenditures
1,610
3,927
1,981
5,261
10,834
Sale of Fixed Assets & Businesses
-
1
14
-
-
Purchase/Sale of Investments
3,302
5,217
17,401
19,451
11,081
Net Investing Cash Flow
12,294
9,143
19,382
24,742
85
Issuance/Reduction of Debt, Net
60
600
1,053
-
-
Net Financing Cash Flow
15,945
5,933
36,447
11,210
1,327
Net Change in Cash
3,138
5,658
16,046
10,028
4,880
Free Cash Flow
2,002
6,288
2,900
1,736
16,963
Net Assets from Acquisitions
7,381
-
-
-
-
Other Sources
-
-
10
40
109
Change in Capital Stock
17,985
6,533
37,499
11,210
36
Exchange Rate Effect
-
-
-
-
-
Other Uses
-
-
23
69
271

About Corestem

View Profile
Address
2/F, I & C Building
Seongnam GY 13486
Korea, Republic Of
Employees -
Website http://www.corestem.com
Updated 09/14/2018
CORESTEM, Inc. engages in the development and distribution of gene therapy products. The company was founded on December 29, 2003 and is headquartered in Seoul, South Korea. .